## Why participate in clinical trials?

Thursday, June 12th, 2025

#### featuring Jennifer Gewandter, Phd, MPH

Associate Professor University of Rochester Medical Center





#### Today's moderator:



Lindsay Colbert Executive Director the Foundation for Peripheral Neuropathy



FoundationForPN.org

#### PLEASE NOTE



#### We're recording!

All our webinars get added to our website.



FoundationForPN.org/past-webinars

Questions? Submit questions anytime in the **questions box.** We will answer as many as we can.

#### Can't hear?

If there's an issue with audio on your tablet or computer, try dialing in by phone.

Check your email for how-to.



#### Today's expert:



#### Jennifer Gewandter PhD, MPH

Associate Professor University of Rochester Medical Center

FoundationForPN.org

Why participate in clinical trials? A discussion of the contributions you can make to the future of neuropathy treatment.

> The Foundation for Peripheral Neuropathy Seminar Series June 12, 2025

> > Jennifer Gewandter, PhD, MPH Associate Professor University of Rochester Medical Center



## Conflict of Interest Disclosure


- I serve as a consultant for Eli Lilly and am an investigator in one of their clinical trials.
- Neurometrix (company that developed the TENS technology I will talk about) provided the TENS units for the clinical trial data I will present.




## Why I study pain and peripheral neuropathy.

- Chronic pain affects over 100 million American adults.
- Costs up to \$635 billion / year in medical costs and lost productivity.
- Opioid epidemic.
- Most treatments for chronic pain are only modestly effective and do not work for everyone.





#### Steps for developing novel medical therapies



**UR** MEDICINE

#### Roles for people living with neuropathy: Research Partners



#### Research partners provide input on:

- Study design
  - Outcomes
  - Entry criteria
  - Design of intervention
- Recruitment materials
  - Language
  - Presentation
  - Images
  - Outreach methods



#### Roles for people living with neuropathy: Research Participants




Research participants:

- Generously donate their time.
- Receive an experimental treatment (or control).
- Complete questionnaires.
  - At visits
  - At home
- Undergo testing.
- Provide biological samples (e.g., blood).



## What I would want my loved one to know about trials.

Why do some people have to get a control (placebo) in trials?







## What I would want my loved one to know about trials.

Why do phase III trials have to be so large?

Variability among people living with peripheral neuropathy/ pain







## What I would want my loved one to know about trials.

## Participation in one clinical trial can have a far-reaching impact.





The Journal of Pain, Vol xxx, No. xxx (xxxx), xxxx: pp xxx-xxx Available online at www.jpain.org and www.sciencedirect.com

Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Randomized Clinical Trial

Jennifer S. Gewandter,\* Eva Culakova,<sup>†</sup> Jenae N. Davis,<sup>‡</sup> Umang Gada,<sup>†</sup> Joseph J. Guido,<sup>†</sup> James D. Bearden,<sup>§</sup> Brain Burnette,<sup>¶</sup> Dhaval Shah,<sup>II</sup> Gary R. Morrow,<sup>†</sup> Karen Mustian,<sup>†</sup> Kathleen A. Sluka,\*\* and Nimish Mohile<sup>††</sup>



## Main entry criteria

- Completed neurotoxic chemotherapy  $\geq$ 3 months ago
  - Platinums, taxanes, vinca alkaloids, bortezomib
- Diagnosed with CIPN (bilateral stocking/glove distribution)
- At least 2 of the following symptoms rated  $\geq$  4 out of 10:
  - Sharp/shooting pain
  - Hot/burning pain
  - Numbness
  - Tingling
  - Cramping



## **TENS Intervention**

Device worn for 5 hours per day.


- Active device: (1-hour sessions every other hour)
  → 3 hours stimulation.
- <u>Placebo device</u>: (2.5-minute sessions every ~2 hours)  $\rightarrow$  7.5 minutes of stimulation.




Treatment period: 6 weeks (primary endpoint).



#### **Participant Flow**









% Change from		Marginal mean group	p-value
baseline		difference [placebo-active]	
		(95% CI)	
-			
Placebo	Active		
-8.7%	-11.6%	1.05 (-0.56, 2.67)	0.199
	baseline Placebo	baseline Placebo Active	baselinedifference [placebo-active] (95% CI)PlaceboActive



Symptom	% Change from		Marginal mean group	p-value
	baseline		difference [placebo-active]	
			(95% CI)	
Primary analysis population (N=142)				
	Placebo	Active		
EORTC-CIPN20	-8.7%	-11.6%	1.05 (-0.56, 2.67)	0.199
Subgroup analyses including only those with $\geq$ 4 at baseline in the particular symptoms				
	Placebo	Active		
Hot/burning pain (N: P=22; A=22)	-28.3%	-49.2%	1.37 (-0.33, 3.08)	0.112
Sharp/shooting pain N: P=24; A=23)	-34.3%	-52.5%	1.21 (-0.36, 2.79)	0.128
Cramping (N: P=18; A=18)	-30.2%	-52.1%	1.35 (-0.32, 3.02)	0.110
Tingling (N: P=50; A=56)	-23.7%	-27.5%	0.24 (-0.60, 1.08)	0.572
Numbness (N: P=50; A=61)	-18.4%	-24.0%	0.27 (-0.51, 1.05)	0.492



Symptom	% Change from		Marginal mean group	p-value
	baseline		difference [placebo-active]	
			(95% CI)	
Primary analysis population (N=142)				
	Placebo	Active		
EORTC-CIPN20	-8.7%	-11.6%	1.05 (-0.56, 2.67)	0.199
Subgroup analyses including only those with $\geq$ 4 at baseline in the particular symptoms				
	Placebo	Active		
Hot/burning pain (N: P=22; A=22)	-28.3%	-49.2%	1.37 (-0.33, 3.08)	0.112
Sharp/shooting pain N: P=24; A=23)	-34.3%	-52.5%	1.21 (-0.36, 2.79)	0.128
Cramping (N: P=18; A=18)	-30.2%	-52.1%	1.35 (-0.32, 3.02)	0.110
Tingling (N: P=50; A=56)	-23.7%	-27.5%	0.24 (-0.60, 1.08)	0.572
Numbness (N: P=50; A=61)	-18.4%	-24.0%	0.27 (-0.51, 1.05)	0.492




Symptom	% Change from baseline		Marginal mean group difference [placebo-active]	p-value
Chronic pain trials are gene		vered to co		
The $\Delta$ in the RCT of duloxetine for CIPN was 0.73.				
Subgroup analyses including only those with $\geq$ 4 at baseline in the particular symptoms				
	Placebo	Active		
Hot/burning pain (N: P=22; A=22)	-28.3%	-49.2%	1.37 (-0.33, 3.08)	0.112
Sharp/shooting pain N: P=24; A=23)	-34.3%	-52.5%	1.21 (-0.36, 2.79)	0.128
Cramping (N: P=18; A=18)	-30.2%	-52.1%	1.35 (-0.32, 3.02)	0.110
Tingling (N: P=50; A=56)	-23.7%	-27.5%	0.24 (-0.60, 1.08)	0.572
Numbness (N: P=50; A=61)	-18.4%	-24.0%	0.27 (-0.51, 1.05)	0.492



## Interindividual variability in pain qualities

Subjects reporting ≥4 out of 10 for each symptom or combination at baseline (Total N=80; 56%)





#### Personalized outcome




Outcome (n=71)	Mean difference (Placebo-active) (95% Cl)	p-value
Mean of symptoms with ≥4 severity**	1.24 (0.07, 2.41)	0.038



#### Impact of this trial...

Which would not have been possible without 151 people who volunteered their time.

• Support funding applications for a phase 3, confirmatory trial.





## **Amplified impact**

Pain Medicine, 2025, 25, 22–29 https://doi.org/10.1093/pm/pnae095 Advance access publication 4 October 2024 Original Research Article NEUROPATHIC PAIN SECTION	US ASSOCIATION FOR THE STUDY OF PAIN US ASSOCIATION FOR THE STUDY OF PAIN US ASSOCIATION FOR THE STUDY OF PAIN	4 additional peer- reviewed publications.
relevance and assay sensitivity analysis from a randomize      Supportive Care in Cancer (2024) 32:675      https://doi.org/10.1007/s00520-024-08878-5      RESEARCH	Implications for Assay Sensitivity Madelai Carla Jo Dale J. L Among Cancer Survivors	6 poster presentations at national & international meetings.
Exploring the reliability and validity of clinically-relevant outcome measures for chemotherapy-induced peripheral neuropathy Robert Knoerl <sup>1</sup> · Michael B. Sohn <sup>2</sup> · Kevin Spath <sup>2</sup> · Brian Burnette <sup>4</sup> · Lori Francar <sup>4</sup> · Karen M. Musti Dhaval Shah <sup>3</sup> · Lynn Gauthier <sup>6</sup> · Jennifer S. Gewandter <sup>7</sup>	Induced Peripheral Neuropathy	2 additional papers in progress.

#### Contribution to science and treatment of CIPN:

- Inform future clinical trial designs (including better understanding currently available outcome measures and developing novel ones)
- Increase understanding of impact of pain associated with neuropathy on important health domains.
- Characterization of analgesic use in patients with CIPN.



#### **Amplified impact**



#### **NEUROPATHIC PAIN SECTION**

Personalized outcomes in neuropathic pain: a clinical relevance and assay sensitivity analysis from a randomize

Supportive Care in Cancer (2024) 32:675 https://doi.org/10.1007/s00520-024-08878-5

RESEARCH

Exploring the reliability and validity of clinically-relevant outcome measures for chemotherapy-induced peripheral neuropathy

Robert Knoerl<sup>1</sup> · Michael B. Sohn<sup>2</sup> · Kevin Spath<sup>2</sup> · Brian Burnette<sup>4</sup> · Lori Francar<sup>4</sup> · Karen M. Mustian<sup>5</sup> · Dhaval Shah<sup>3</sup> · Lynn Gauthier<sup>6</sup> · Jennifer S. Gewandter<sup>7</sup>

Mean of Daily Versus Single Week Recall-Based Pain Quality Assessments in Neuropathic Pain Trials: Implic<u>ations for Assay Sensitivity</u>

UBLISHED B

ELSEVIEF

Madelai Carla Jo Dale J. 1 e Kploring Analgesic Use Patterns Among Cancer Survivors With Chronic Chemotherapy-Induced Peripheral Neuropathy

The Journal of Pain, Vol xxx, No. xxx (xxxx), xxxx: xxx

Available online at www.jpain.org and www.sciencedirect.com

Robert Knoerl, PhD, RN, Michael B. Sohn, PhD, Melyssa Foust, MSN, RN, OCN®, Lori Francar, MLIS, BSN, RN, Mark A. O'Rourke, MD, Gary R. Morrow, PhD, MS, Karen M. Mustian, PhD, MPH, Lynn Gauthier, PhD, and Jennifer S. Gewandter, PhD, MPH 4 additional peerreviewed publications.

6 poster presentations at national & international meetings.

2 additional papers in progress.



**UR** MEDICINE

MEDICINE of THE HIGHEST ORDER

OXFO

IS ASSOCIATION FOR THE STUDY OF PA

#### **Amplified impact**



All the great things these Brillant young people will do in the world.



## Where to find opportunities

- Foundations or patient advocacy group websites & listservs.
- Clinicaltrials.gov
- Academic medical centers near you.
  - Social media pages.
  - Research volunteer registries.
  - Email researchers directly.
    - Find them on their department websites (Anesthesiology or Neurology most likely for peripheral neuropathy).
- Ask your doctor and look around the office for flyers.
- Look for flyers in your community.



## Many thanks

#### The participants who made our clinical trial possible.

#### <u>Funding:</u>

- R21 CA235389-01A1
- UG1CA189961
- 1K24NS126861
- U24NS113784
- 1R01AR080627 (PI: Geha)
- 1R01NS126451 (PI: Geha)

#### <u>Colleagues</u>

- Roy Freeman, MD
- Robert Edwards, PhD
- Paul Geha, MD
- Dale, Langford, PhD
- Michael McDermott, PhD
- Michael Sohn, PhD
- Kathleen Sluka, PhD
- Ajay Wasan, MD
- Gordon Smith, MD
- Simon Hauroutunian, PhD
- Lynn Gautier, PhD
- Annie Philip, MD
- Mark Williams, MD
- John Markman, MD
- Nimish Mohile, MD



#### Current mentees

#### Junior Faculty

- Robert Knoerl, PhD
- Umang Gada, MS *Post-doc*
- Karim Saab, MD

#### Residents/Fellows

Soroush Besharat, MD

#### Medical Students

- Maddy Rangel
- Jithin George
- Jeremy Huang
- Saanya Lingineni
- Joyce Liu
- Felicia Ko
- Abe Choe

#### <u>Coordinators / administrator</u>

- Valerie Chiodo
- Rachel DeGuzman
- Tammy Ortiz

# Thanks for joining us! **ANY QUESTIONS?!**





HOW WAS IT?

Let us know! Take our short **survey** after the webinar




SUPPORT US Donate so we can do more webinars and educational programs





CONTACT US info@tffpn.org 847-883-9942

*th*e Foundation *for* Peripheral Neuropathy 2700 Patriot Blvd, Ste 250 Glenview, IL 60026





Links in our Linktree: linktr.ee/tffpn

#### FoundationForPN.org